환자 혈액 관리 시장 : 제품 유형, 치료법, 용도, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Patient Blood Management Market is projected to grow by USD 24.36 billion at a CAGR of 6.71% by 2032.

Patient Blood Management Executive Summary

Patient Blood Management, or PBM, is an evidence-based, multidisciplinary approach that improves patient outcomes by diagnosing and treating anemia, minimizing blood loss, and optimizing tolerance of anemia before transfusion is considered. The World Health Organization identifies PBM as a patient-safety and health-system efficiency priority, while AABB and major clinical societies continue to reinforce restrictive red blood cell transfusion strategies when clinically appropriate.

For hospitals, surgical centers, blood services, diagnostic developers, and digital health providers, PBM has moved from a clinical protocol to a strategic operating model. Demand is shaped by aging populations, high surgical volumes, chronic disease burden, obstetric and trauma care needs, and persistent pressure on blood supply chains, making transfusion stewardship, perioperative anemia management, cell salvage, hemostasis optimization, and point-of-care coagulation testing core industry themes.

Transformative Shifts in Patient Blood Management

The PBM landscape is shifting from product-centered transfusion support to outcome-centered blood conservation. Health systems are standardizing preoperative anemia screening, iron therapy pathways, antifibrinolytic use, minimally invasive surgery, surgical hemostasis, cell salvage, and evidence-based transfusion thresholds to reduce avoidable allogeneic blood exposure and transfusion-associated risk.

This transition is being accelerated by blood shortages, donor demographic constraints, stronger hemovigilance, antimicrobial and infection-control expectations, and reimbursement pressure linked to quality outcomes. Industry leaders are responding with integrated PBM platforms, rapid diagnostics, clinical decision support, automated inventory management, and education programs that align surgeons, anesthesiologists, intensivists, hematologists, obstetric teams, and transfusion services around safer and more efficient blood utilization.

Cumulative Impact of Artificial Intelligence in PBM

Artificial intelligence is creating cumulative value across PBM by improving identification of patients at risk of anemia, perioperative bleeding, transfusion reactions, and prolonged recovery. AI-enabled models can support earlier anemia workups, predict surgical blood requirements, optimize crossmatch planning, flag inappropriate transfusion orders, and help blood banks forecast demand using historical utilization, seasonality, procedure schedules, emergency activity, and inventory constraints.

The greatest opportunity is not automation alone, but safer decision support embedded into clinical workflows. Hospitals must validate algorithms locally, monitor bias, protect patient data, document model performance, and keep clinicians accountable for final decisions. When governed properly, AI can strengthen transfusion stewardship, reduce wastage, improve stock rotation, and increase responsiveness during shortages, mass-casualty events, or high-acuity care surges.

Key Regional Patient Blood Management Insights

Asia-Pacific is expanding PBM adoption as China, India, Japan, South Korea, and Australia address high procedure volumes, anemia burden, maternal health needs, and uneven access to safe blood components. National hospital modernization programs, surgical capacity expansion, and digital health adoption are reinforcing demand for anemia management, rapid coagulation diagnostics, and transfusion governance. North America remains a mature PBM environment, supported by AABB standards, hospital accreditation expectations, electronic health records, quality improvement programs, and strong uptake of restrictive transfusion guidelines in perioperative, critical care, and medical settings. Latin America shows rising interest in transfusion stewardship, particularly in Brazil and Mexico, although access to diagnostics, standardized hemovigilance, and specialist transfusion medicine resources varies across health systems.

Europe benefits from established national blood systems, EU-level safety and quality alignment, and long-standing PBM programs in countries such as Germany, France, Italy, Spain, and the United Kingdom, where hemovigilance and preoperative anemia management are increasingly embedded in hospital practice. The Middle East is investing in tertiary care, trauma systems, transplant services, oncology, and complex surgery, creating demand for advanced blood management protocols across GCC and neighboring markets. Africa faces the most significant infrastructure and donor-supply constraints, making safe blood access, voluntary donation systems, anemia prevention, maternal care, infectious disease screening, and scalable PBM education essential priorities for resilient healthcare delivery.

Key Group-Level Patient Blood Management Insights

ASEAN countries are advancing PBM through hospital modernization, expanding surgical capacity, and growing demand for safer transfusion practices, with adoption influenced by public-private healthcare investment and variability in national blood services. The GCC is prioritizing PBM as part of broader healthcare transformation, particularly in high-acuity specialties, trauma care, oncology, transplantation, obstetrics, and complex cardiovascular surgery. The European Union provides one of the strongest frameworks for harmonized blood safety standards, hemovigilance, clinical quality improvement, and cross-border regulatory consistency, supporting wider implementation of evidence-based transfusion stewardship.

BRICS markets combine large patient populations with expanding tertiary care capacity, high anemia burden in several settings, and increasing investment in diagnostics and hospital infrastructure, creating strong need for anemia management and transfusion optimization. G7 countries lead in clinical guideline adoption, digital health integration, hospital quality measurement, and high-value care models that support PBM as a patient safety and cost-efficiency strategy. NATO countries add a defense-health dimension, where blood readiness, trauma medicine, emergency preparedness, and resilient supply chains make PBM relevant to both civilian healthcare systems and military medical planning.

Key Country-Level Patient Blood Management Insights

The United States leads in PBM implementation through hospital quality programs, clinical decision support, electronic ordering controls, and AABB-aligned transfusion practices, while Canada emphasizes national blood operator coordination, provincial health-system planning, and evidence-based utilization. Mexico and Brazil are strengthening transfusion services as surgical, oncology, trauma, and obstetric demand expands, with opportunities centered on standardized testing, hemovigilance, and workforce training. The United Kingdom, Germany, France, Italy, and Spain support PBM through mature hospital networks, national blood systems, hemovigilance infrastructure, and growing attention to preoperative anemia management, perioperative blood conservation, and restrictive transfusion thresholds.

Russia has demand tied to trauma, oncology, cardiovascular care, transplant medicine, and regional healthcare modernization. China and India represent major PBM growth environments due to population scale, anemia prevalence, surgical expansion, maternal health needs, and investment in hospital infrastructure and diagnostics. Japan, Australia, and South Korea are advanced PBM adopters with strong clinical governance, high technology penetration, aging population needs, and demand for precision diagnostics, perioperative blood conservation, cell salvage, point-of-care coagulation testing, and digital transfusion stewardship.

Actionable Recommendations for PBM Leaders

Industry leaders should position PBM as an enterprise-wide patient safety strategy rather than a narrow blood utilization initiative. High-impact actions include standardizing anemia screening before elective surgery, integrating iron and hemostasis pathways, expanding cell salvage where appropriate, deploying evidence-based transfusion triggers, and tracking outcomes such as transfusion rates, complications, length of stay, readmissions, blood component wastage, and adherence to clinical protocols.

Commercial teams should prioritize interoperable digital tools, rapid diagnostics, clinical decision support, education partnerships, and implementation support that helps hospitals translate guidelines into measurable practice change. Leaders should also build regional strategies around local blood availability, regulatory requirements, reimbursement models, procurement pathways, hemovigilance maturity, and workforce readiness to ensure PBM programs are clinically credible, operationally scalable, and financially sustainable.

Research Methodology

This executive summary is based on triangulated secondary research from authoritative public sources, including the World Health Organization, AABB, ISBT, national blood services, regulatory agencies, peer-reviewed journals, clinical guidelines, hospital quality frameworks, and international health databases from organizations such as the OECD and World Bank.

The analysis applies evidence screening, source validation, regional mapping, and keyword-focused synthesis to identify strategic PBM trends. Insights were prioritized when supported by clinical consensus, regulatory guidance, hemovigilance evidence, blood safety documentation, or documented health-system practice rather than unverified commercial claims, market sizing, or forecasting assumptions.

Conclusion

Patient Blood Management is becoming a central pillar of safe, efficient, and resilient healthcare delivery. Its value is strongest where hospitals combine early anemia management, blood conservation, hemostasis optimization, evidence-based transfusion decisions, and continuous outcome measurement across surgical, medical, obstetric, trauma, oncology, and critical care pathways.

As blood supply constraints, demographic pressure, quality requirements, and emergency preparedness needs intensify, PBM will remain a priority for providers, policymakers, and industry partners. Organizations that align clinical evidence, digital intelligence, diagnostics, education, and implementation support will be best positioned to lead the next phase of transfusion stewardship and patient-centered blood management.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Patient Blood Management Market, by Product Type

• 7.1. Antifibrinolytics
• 7.2. Autotransfusion Systems
• 7.3. Blood Component Separation Systems
• 7.4. Blood Management Disposables
  • 7.4.1. Cell Washing Kits
  • 7.4.2. Collection Reservoirs
  • 7.4.3. Filtration Devices
• 7.5. Coagulation Monitoring Systems
  • 7.5.1. Laboratory Analyzers
  • 7.5.2. Point Of Care Devices
• 7.6. Hemostats And Sealants
  • 7.6.1. Sealant Systems
  • 7.6.2. Topical Hemostats
• 7.7. Volume Expanders

8. Patient Blood Management Market, by Therapy Type

• 8.1. Allogeneic Transfusion
• 8.2. Autologous Transfusion
• 8.3. Cell Salvage
• 8.4. Hemostasis Management
  • 8.4.1. Antifibrinolytic Therapy
  • 8.4.2. Topical Hemostats Therapy
• 8.5. Perioperative Blood Conservation
  • 8.5.1. Intraoperative Techniques
  • 8.5.2. Postoperative Care
  • 8.5.3. Preoperative Optimization

9. Patient Blood Management Market, by Application

• 9.1. Cardiovascular Surgery
  • 9.1.1. Aortic Surgery
  • 9.1.2. Coronary Artery Bypass Grafting
  • 9.1.3. Valve Replacement Procedures
• 9.2. Elective Surgery
• 9.3. Obstetrics
• 9.4. Oncology Treatments
  • 9.4.1. Chemotherapy
  • 9.4.2. Radiotherapy
• 9.5. Trauma

10. Patient Blood Management Market, by End User

• 10.1. Ambulatory Surgical Centers
• 10.2. Clinics
• 10.3. Hospitals
• 10.4. Specialty Centers
  • 10.4.1. Cancer Treatment Centers
  • 10.4.2. Cardiac Care Centers
  • 10.4.3. Trauma Centers

11. Patient Blood Management Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Patient Blood Management Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Patient Blood Management Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Baxter International Inc.
• 15.2. BioMerieux SA
• 15.3. CSL Limited
• 15.4. Danaher Corporation
• 15.5. Fresenius Kabi AG
• 15.6. Grifols, S.A.
• 15.7. Haemonetics Corporation
• 15.8. LivaNova PLC
• 15.9. Macopharma SA
• 15.10. Octapharma AG
• 15.11. Roche Diagnostics International AG
• 15.12. Terumo Corporation
• 15.13. ZOLL Medical Corporation